Literature DB >> 18090546

Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis.

Barbara Peters1, Olaf Grisk, Bertram Becher, Heike Wanka, Beate Kuttler, Jan Lüdemann, Gerd Lorenz, Rainer Rettig, John J Mullins, Jörg Peters.   

Abstract

OBJECTIVE: Prorenin has been associated with cardiovascular disease and the development of glomerulosclerosis via a renin/prorenin receptor. In cyp1a1ren-2 transgenic rats, prorenin levels and arterial pressure can be increased by oral administration of indole-3-carbinol (I3C). The transgenic strain has been used as a model of malignant hypertension.
METHODS: The present study was designed to test the hypotheses that (i) low doses of I3C would result in dose-dependent sustained increases in arterial pressure without signs of malignancy, making cyp1a1ren-2 transgenic rats a useful model to study nonmalignant hypertension, and (ii) cyp1a1ren-2 transgenic rats would develop glomerulosclerosis when they were chronically exposed to 0.125% I3C in their diet.
RESULTS: I3C treatment for 2 weeks resulted in increases of plasma prorenin concentrations and arterial pressure in a dose-dependent manner. Rats thrived well over a period of 12 weeks on dietary I3C concentrations (wt/wt) of 0.125%. Plasma prorenin concentration rose from 0.1 +/- 0.1 microg to 17.9 +/- 5.0 mug angiotensin I/ml per h (P < 0.01) and mean arterial pressure increased to a plateau of 170 +/- 5 mmHg (P < 0.001) between weeks 6 and 12. After 12 weeks of 0.125% I3C, rats exhibited moderate hypertensive renal vasculopathy, but no histological signs of glomerulosclerosis.
CONCLUSIONS: The cyp1a1ren-2 transgenic rat model allows for chronic dose-dependent titration of arterial pressure by a simple and non-invasive intervention, making this strain a useful model to study malignant and nonmalignant arterial hypertension. High circulating prorenin levels per se do not cause glomerulosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090546     DOI: 10.1097/HJH.0b013e3282f0ab66

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  31 in total

Review 1.  Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease.

Authors:  Helmy M Siragy; Robert M Carey
Journal:  Am J Nephrol       Date:  2010-05-18       Impact factor: 3.754

Review 2.  The (pro)renin receptor and its interaction partners.

Authors:  Jörg Peters
Journal:  Pflugers Arch       Date:  2017-06-15       Impact factor: 3.657

3.  (Pro)renin Receptor Is an Amplifier of Wnt/β-Catenin Signaling in Kidney Injury and Fibrosis.

Authors:  Zhen Li; Lili Zhou; Yongping Wang; Jinhua Miao; Xue Hong; Fan Fan Hou; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2017-03-07       Impact factor: 10.121

Review 4.  Renin and prorenin receptor in hypertension: what's new?

Authors:  Genevieve Nguyen
Journal:  Curr Hypertens Rep       Date:  2011-02       Impact factor: 5.369

Review 5.  Key developments in renin-angiotensin-aldosterone system inhibition.

Authors:  Bruno Sevá Pessôa; Nils van der Lubbe; Koen Verdonk; Anton J M Roks; Ewout J Hoorn; A H Jan Danser
Journal:  Nat Rev Nephrol       Date:  2012-11-20       Impact factor: 28.314

Review 6.  What is the role of renin inhibition in the treatment of diabetic kidney disease?

Authors:  Radko Komers
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

7.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

Review 8.  Secretory and cytosolic (pro)renin in kidney, heart, and adrenal gland.

Authors:  Jörg Peters
Journal:  J Mol Med (Berl)       Date:  2008-03-27       Impact factor: 4.599

Review 9.  Aldosterone in salt-sensitive hypertension and metabolic syndrome.

Authors:  Toshiro Fujita
Journal:  J Mol Med (Berl)       Date:  2008-04-25       Impact factor: 4.599

10.  Lack of cardiac fibrosis in a new model of high prorenin hyperaldosteronism.

Authors:  Jörg Peters; Torsten Schlüter; Thomas Riegel; Barbara S Peters; Andreas Beineke; Ulrike Maschke; Norbert Hosten; John J Mullins; Rainer Rettig
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-09-11       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.